Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Total Liabilities (2016 - 2025)

Assembly Biosciences (ASMB) has 11 years of Total Liabilities data on record, last reported at $57.3 million in Q3 2025.

  • For Q3 2025, Total Liabilities fell 22.83% year-over-year to $57.3 million; the TTM value through Sep 2025 reached $57.3 million, down 22.83%, while the annual FY2024 figure was $85.8 million, 10.36% down from the prior year.
  • Total Liabilities reached $57.3 million in Q3 2025 per ASMB's latest filing, down from $62.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $95.7 million in Q4 2023 and bottomed at $9.9 million in Q3 2023.
  • Average Total Liabilities over 5 years is $43.8 million, with a median of $30.3 million recorded in 2021.
  • Peak YoY movement for Total Liabilities: tumbled 49.65% in 2022, then soared 648.96% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $22.1 million in 2021, then dropped by 13.56% to $19.1 million in 2022, then skyrocketed by 400.4% to $95.7 million in 2023, then fell by 10.36% to $85.8 million in 2024, then tumbled by 33.22% to $57.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $57.3 million in Q3 2025, $62.7 million in Q2 2025, and $71.9 million in Q1 2025.